<DOC>
	<DOCNO>NCT00889408</DOCNO>
	<brief_summary>This phase I dose escalation study DT2219ARL treatment relapse refractory B-lineage leukemia lymphoma . Patients receive single course DT2219ARL 4 hour infusion day 1 , 3 , 5 , 8 . Weekly follow-up continue day 29 , time disease reassessment do . For patient remission , follow-up continue monthly disease progression start new treatment . Otherwise day 29 final study visit ongoing toxicity . This phase I study use Continual Reassessment Method ( CRM ) establish maximum tolerate dose ( MTD ) DT2219ARL . Up 3 dose level test additional dose level ( -1 ) dose level 1 prof toxic . The goal CRM identify dose level correspondence desire toxicity rate 33 % less use grade 3 4 capillary leak syndrome grade 3 great toxicity attribute DT2219ARL target toxicity ( base CTCAE version 4 ) .</brief_summary>
	<brief_title>DT2219ARL Relapsed Refractory CD19 ( + ) , CD 22 ( + ) B-Lineage Leukemia Or Lymphoma</brief_title>
	<detailed_description>The current study initially conduct University Texas Scott White Cancer Institute ( A. Frankel , MD - PI ) M. D. Anderson Cancer Center 15 evaluable patient enrol end 2011 ( table 1 ) . The 3rd patient enrol 40 μg/kg dose cohort first experience dose limit toxicity ( grade 3 neurological : low extremity weakness ) receive 3 4 planned dos . Per study design , 40 μg/kg would enroll additional 3 patient confirm dose limit toxicity . It point Texas center discontinue involvement study . Approximately 15 month last patient enrol original study plan , protocol redesign Masonic Cancer Center University Minnesota , build experience 1st 15 patient enrol Texas center . To increase efficiency , study design change standard 3 x 3 dose escalation Continuous Reassessment Method ( CRM ) model test 3 dos level ( 40 , 60 , 80 ug/kg ) add feature dose level -1 ( 30 ug/kg ) event dose level 1 prof toxic . The maximum tolerate dose identified 20 evaluable patient enrol .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<criteria>Histologic verification Bcell lineage leukemia B cell nonHodgkin lymphoma evidence relapse/refractory disease presence CD19 and/or CD22 flow cytometry immunohistochemistry bone marrow aspirate , peripheral blood node biopsy Disease refractory conventional therapy therapy higher priority Age ≥ 12 year Karnofsky Performance status ≥ 60 % , less 16 year age , Lansky Play Score ≥ 60 ( appendix II ) Patients must recover effect prior therapy least 2 week elapse since last dose chemotherapy ; however patient recover effect previous treatment &gt; 50 % rise peripheral blast count ( confirm twice ) &gt; 50 % growth lymph node immediately eligible Patients relapse follow autologous allogeneic BMT eligible In order prevent tumor lysis syndrome , leukemia patient must peripheral blast count 50 x 109/L . This achieve hydroxyurea cytoreduction , prior start DT2219ARL follow patient peripheral blast WBC &gt; 50 x 109/L , give hydroxyurea 15 g daily 5 day reduce WBC 50 x 109/L Adequate organ function within 14 day ( 30 day cardiac pulmonary ) treatment start define : Creatinine : ≤ 1.5 x upper limit institutional normal ( ULN ) Hepatic : SGOT ( AST ) SGPT ( ALT ) &lt; 2.5 x ULN total bilirubin &lt; /= 1.5 x ULN General health : Serum albumin ≥ 3.0g/dL Pulmonary : PFTs &gt; 50 % symptomatic prior know impairment Cardiac : LVEF ECHO MUGA ≥ 40 % Agrees stay within Twin Cities metropolitan area ( i.e . within 30 mile study center ) duration treatment ( least 24 hour last dose ) 2 ) capable caregiver Women childbearing potential men advise agree practice effective method contraception course study Voluntary write consent Presence leukemic infectious pulmonary parenchymal disease Presence active CNS leukemia . CSF &lt; 5 WBC/uL exclude patient Presence uncontrolled systemic infection Documented uncontrolled seizure disorder abnormal neurological examination seizure disorder control medication ( i.e . seizures previous 6 month ) exclude patient Documented penicillin cephalosporin allergy Pregnant lactate Women child bear potential must negative pregnancy test within 14 day study treatment start</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>childhood immunoblastic large cell lymphoma</keyword>
	<keyword>B-cell adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>Waldenström macroglobulinemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>childhood Burkitt lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>noncutaneous extranodal lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
</DOC>